Method for treating hypothyroidism

• US 20040156893A1
• Filed: 02/11/2003
• Published: 08/12/2004
• Est. Priority Date: 02/11/2003
• Status: Abandoned Application

• Current Assignee: North Shore-Long Island Jewish Research Institute
• Original Assignee: North Shore-Long Island Jewish Research Institute
• Inventors: Klein, Irwin, Ojamaa, Kaie, Danzi, Sara
• Application Number:
  US10/364,800
• Publication Number:
  US 20040156893A1
• Time in Patent Office: Days
• US Class Current: 424/457
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61P 3/14 for calcium homeostasis vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4

Abstract

The present invention provides a method for treatment of hypothyroidism in an adult comprising the long-term administration of T₃ at a dose of 0.005-0.03 μg/kg body weight/hour/day.

Claims

1. A method for treating hypothyroidism in an adult subject having hypothyroidism, comprising the long-term administration to the adult subject of T₃ at a dose of 0.005-0.03 μ

g/kg body weight/hour/day effective to treat hypothyroidism in the subject.

2. The method of claim 1, where T₃ is administered at a dose of 0.0075-0.02 μ

g/kg body weight/hour/day.

3. The method of claim 2, where T₃ is administered at a dose of 0.01-0.01.5 μ

g/kg body weight/hour/day.

4. The method of claim 2, where T₃ is administered at a dose of about 0.01 μ

g/kg body weight/hour/day.

5. The method of claim 1, wherein the daily dose of T₃ is 8-50 μ

g.

6. The method of claim 2, wherein the daily dose of T₃ is 12-35 μ

g.

7. The method of claim 3, wherein the daily dose of T₃ is 17-25 μ

g.

8. The method of claim 4, wherein the daily dose of T₃ is about 17 μ

g.

9. The method of claim 1, wherein T₃ is formulated in a pharmaceutically acceptable carrier.

10. The method of claim 9, wherein T₃ is administered in a sustained-release formulation.

11. The method of claim 1, wherein T₃ is administered daily.

12. The method of claim 1, wherein T₃ is administered orally.

13. The method of claim 1, wherein T₃ is administered is by infusion.

14. The method of claim 10, wherein T₃ is administered daily.

15. The method of claim 10, wherein T₃ is administered orally.

16. The method of claim 1, wherein T₃ is administered orally in a sustained-release formulation once a day.

17. The method of claim 1, wherein the adult has a deficiency in converting T₄ to T₃.

18. The method of claim 1, wherein T₃ is administered in the absence of administration of a therapeutic dose of T₄.

19. A formulation wherein T₃ is released at a dose of 0.005-0.03 μ

g/kg body weight/hour/day.

20. The formulation of claim 19, where T₃ is released at a dose of 0.0075-0.02 μ

g/kg body weight/hour/day.

21. The formulation of claim 20, where T₃ is released at a dose of 0.01-0.015 μ

g/kg body weight/hour/day.

22. The formulation of claim 20, where T₃ is released at a dose of about 0.01 μ

g/kg body weight/hour/day.

23. The formulation of claim 19, wherein the daily dose of T₃ is 8-50 μ

g.

24. The formulation of claim 20, wherein the daily dose of T₃ is 12-35 μ

g.

25. The formulation of claim 21, wherein the daily dose of T₃ is 17-25 μ

g.

26. The formulation of claim 22, wherein the daily dose of T₃ is about 17 μ

g.